Belite Bio (BLTE) said Monday it has priced an underwritten public offering of about 2.3 million American depositary shares at $154 each.
The company said it has also granted underwriters a 30-day option to purchase up to 340,909 additional depositary shares.
The company said it expects gross proceeds of about $350 million from the offering, which is expected to close about Wednesday.
The company said it plans to use net proceeds of the offering for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.